C6orf62

Across TCGA pan-cancer cohorts, C6orf62 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C6orf62 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher C6orf62 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C6orf62 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and SARC are the cancer types where C6orf62 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.313	0.924	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.629	.020	16	view →
SARC	OS	Median	All	0.178	0.745	.008	6	view →
BLCA	DFS	Median	III,IV	0.139	0.572	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C6orf62–BRCA (OS)

Open the BRCA breakdown →